No headlines found.
Business Wire (Wed, 13-May 7:00 AM ET)
PureTech Announces Annual Results for Year Ended December 31, 2025
Business Wire (Wed, 29-Apr 2:01 AM ET)
Business Wire (Wed, 29-Apr 2:00 AM ET)
Business Wire (Mon, 27-Apr 7:05 AM ET)
Business Wire (Wed, 22-Apr 7:00 AM ET)
PureTech Health: Notice of Results
Business Wire (Mon, 13-Apr 2:05 AM ET)
Business Wire (Thu, 2-Apr 8:19 AM ET)
Business Wire (Thu, 2-Apr 7:08 AM ET)
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Puretech Health PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol PRTC.
As of June 10, 2026, PRTC stock price was flat at $17.42 with million shares trading.
PRTC has a market cap of $424.03 million. This is considered a Small Cap stock.
Last quarter Puretech Health PLC - American Depositary Shares reported $5 million in Revenue and -$.46 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $3.34.
In the last 3 years, PRTC traded as high as $34.00 and as low as $13.30.
PRTC has underperformed the market in the last year with a return of -4.9%, while the SPY ETF gained +22.2%. In the last 3 month period, PRTC fell short of the market, returning +6.2%, while SPY returned +7.2%. However, in the most recent 2 weeks PRTC has outperformed the stock market by returning 0.0%, while SPY returned -3.4%.
PRTC support price is $17.03 and resistance is $17.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRTC shares will trade within this expected range on the day.